Clorprenaline

Clorprenaline

SCHEMBL406791

CC(C)NCC(O)c1ccccc1Cl.Cl

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Clorprenaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ADRB2 known ✓ P07550 5/20 0.97
▸ ADRB1 known ✓ P08588 5/20 0.97
▸ ADRB3 known ✓ P13945 3/20 0.48
▸ BLM P54132 1/20 0.64
▸ CYP2D6 P10635 2/20 0.61
▸ HIF1A Q16665 2/20 0.61
▸ NFKB1 P19838 1/20 0.61
▸ AOC3 Q16853 1/20 0.50
▸ MEN1 O00255 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Clorprenaline SCHEMBL30394245 1.00 ADRB2 (0.97) ADRB2ADRB1BLMCYP2D6HIF1A
Clorprenaline SCHEMBL2852861 0.98 ADRB2 (0.93) ADRB2ADRB1BLMCYP2D6HIF1A
Clorprenaline SCHEMBL29417577 0.98 ADRB2 (0.93) ADRB2ADRB1BLMCYP2D6HIF1A
Clorprenaline SCHEMBL15568417 0.98 ADRB2 (0.93) ADRB2ADRB1BLMCYP2D6HIF1A
Clorprenaline SCHEMBL45370 0.98 ADRB2 (0.93) ADRB2ADRB1BLMCYP2D6HIF1A
Clorprenaline SCHEMBL250611 0.98 ADRB2 (1.00) ADRB2ADRB1BLMCYP2D6HIF1A
Clorprenaline SCHEMBL29483933 0.98 ADRB2 (1.00) ADRB2ADRB1BLMCYP2D6HIF1A
Clorprenaline SCHEMBL2852860 0.97 ADRB2 (0.90) ADRB2ADRB1BLMCYP2D6HIF1A
Clorprenaline SCHEMBL1650012 0.93 ADRB2 (0.90) ADRB2ADRB1BLMCYP2D6HIF1A
Clorprenaline SCHEMBL122700 0.91 ADRB2 (0.85) ADRB2ADRB1BLMCYP2D6HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 551 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023091964-A2 COMPOSITIONS AND METHODS FOR THE INHIBITION OF TUMOR METASTASIS AND HORIZONTAL GENE TRANSFER THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE (US) 2023-05-25 — — WO claimed
CN-109254050-A A kind of preparation method and application of clenbuterol hydrochloride Electrochemiluminescsensor sensor 济南大学 2019-01-22 — — CN claimed
CN-109254060-A A kind of preparation method and application of clenbuterol hydrochloride electrochemical sensing electrode 济南大学 2019-01-22 — — CN claimed
CN-207751925-U One kind detecting the multi-component sensor of clenbuterol hydrochloride based on molecular engram 山东省环境保护科学研究设计院 2018-08-21 — — CN claimed
CN-107884503-A 22 kinds of detection methods for illegally adding relieving cough and asthma class medicine in asthma-relieving bolus of gecko 广西壮族自治区食品药品检验所 2018-04-06 — — CN claimed
CN-105137063-B A kind of preparation method of the unmarked electrochemical immunosensor for clenbuterol hydrochloride detection UNIVERSITY OF JINAN (CN) 2016-04-20 — — CN claimed
CN-105137063-A Making method of unmarked electrochemical immunosensor for clenbuterol hydrochloride detection UNIV JINAN 2015-12-09 — — CN claimed
CN-104502429-B The preparation method and application of unmarked electrogenerated chemiluminescence clenbuterol hydrochloride immunosensor UNIVERSITY OF JINAN (CN) 2015-10-21 — — CN claimed
CN-103558336-B Portable food safety inspection reagent as well as preparation method and application thereof NINGBO INST MATERIALS TECHNOLOGY & ENG CAS 2015-07-01 — — CN claimed
CN-104502429-A Preparation method for unmarked electrogenerated chemiluminescence clenbuterol immune sensor and application thereof UNIV JINAN 2015-04-08 — — CN claimed
US-20030236298-A1 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders ATHEROGENICS PHARMACEUTICALS, INC. 2003-12-25 — — US claimed
CN-1447804-A 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders ATHEROGENICS INC (US) 2003-10-08 — — CN claimed
US-6608101-B1 Inflammatory disorders; 3-(2,4-dimethoxy-5-(thien-2-yl)phenyl)-1-(4-carboxymethoxy-3,5 -dimethoxyphenyl)-2-propen-1-one; ATHEROGENICS, INC. 2003-08-19 — — US claimed
EP-1330448-A2 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS Atherogenics, Inc. (US) 2003-07-30 — — EP claimed
CN-1362231-A Nano Haizhu Chuanxiding medicine and its preparation YANG MENGJUN (CN) 2002-08-07 — — CN claimed
WO-2001098291-A2 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPEN-1-ONES AND THEIR USE TO TREAT VCAM-1 MEDIATED DISORDERS ATHEROGENICS, INC. (US) 2001-12-27 — — WO claimed
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 — — US claimed
US-5700410-A Method of manufacturing wax matrices NIPPON SHINYAKU CO., LTD. (JP) 1997-12-23 — — US claimed
EP-0580860-B1 METHOD OF MANUFACTURING SOLID DISPERSION NIPPON SHINYAKU CO LTD (JP) 1997-10-22 — — EP claimed
EP-0189861-A2 Percutaneous absorption accelerator for ionic water-soluble medicine SHOWA DENKO KABUSHIKI KAISHA (JP) 1986-08-06 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236298-A1 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders VCAM1, ICAM1, ITGB1 ADRB2 86/4885ADRB1 24/4885ADRB3 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback